Ticker League

EBITDA Margin for Regeneron Pharmaceuticals (REGN)

As of · Reported

Metric

TTM

38.5%

YoY change

+3.12pp

Trough year (2002)

-516.2%

Peak year (2021)

60.2%

EBITDA Margin history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

Latest: 40.6%

EBITDA Margin change chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

Latest: +3.12pp

EBITDA Margin history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

  • 202540.6%+3.12pp
  • 202437.4%+1.67pp
  • 202335.8%-7.43pp
  • 202243.2%-16.96pp
  • 202160.2%+11.87pp
  • 202048.3%+7.58pp
  • 201940.7%+0.03pp
  • 201840.7%+2.38pp
  • 201738.3%+8.64pp
  • 201629.7%-2.36pp
  • 201532.0%+1.32pp
  • 201430.7%-7.35pp
  • 201338.1%+2.03pp
  • 201236.0%+74.28pp
  • 2011-38.3%-21.77pp
  • 2010-16.5%-1.88pp
  • 2009-14.6%+11.12pp
  • 2008-25.7%+39.93pp
  • 2007-65.6%+54.95pp
  • 2006-120.6%-18.02pp
  • 2005-102.6%-142.36pp
  • 200439.8%+198.95pp
  • 2003-159.2%+357.02pp
  • 2002-516.2%-153.90pp
  • 2001-362.3%-327.11pp
  • 2000-35.2%+23.95pp
  • 1999-59.1%-34.26pp
  • 1998-24.9%+3.23pp
  • 1997-28.1%+18.38pp
  • 1996-46.5%-40.27pp
  • 1995-6.2%+101.55pp
  • 1994-107.8%+229.03pp
  • 1993-336.8%-195.05pp
  • 1992-141.7%-21.19pp
  • 1991-120.5%-60.55pp
  • 1990-60.0%—

EBITDA Margin values are taken from Regeneron Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA Margin at Regeneron Pharmaceuticals (REGN)

According to Regeneron Pharmaceuticals's latest reported financial statements, the company's latest reported EBITDA margin is 38.5%. EBITDA margin is EBITDA divided by revenue — earnings before interest, taxes, depreciation, and amortization as a percentage of sales. By stripping out non-cash charges and capital-structure effects, it approximates operating cash profitability and is widely used to compare companies with different asset bases and leverage.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

In 2025, Regeneron Pharmaceuticals (REGN) EBITDA margin totalled 40.57% – expanded 3.1 percentage points year-over-year.

2021 marks the peak EBITDA margin at 60.16%, with the historical low of -516.19% recorded in 2002.

Regeneron Pharmaceuticals EBITDA Margin by Year

Regeneron Pharmaceuticals EBITDA Margin 2025: 40.6%

Regeneron Pharmaceuticals posted EBITDA margin of 40.57% in 2025, expanded 3.1 percentage points from 2024.

Regeneron Pharmaceuticals EBITDA Margin 2024: 37.4%

In 2024, Regeneron Pharmaceuticals reported EBITDA margin of 37.45%, expanded 1.7 percentage points from 2023.

Regeneron Pharmaceuticals EBITDA Margin 2023: 35.8%

Regeneron Pharmaceuticals EBITDA margin in 2023 was 35.78%, contracted 7.4 percentage points from 2022.

Regeneron Pharmaceuticals EBITDA Margin 2022: 43.2%

2022's EBITDA margin for Regeneron Pharmaceuticals came in at 43.21%, contracted 17.0 percentage points from 2021.

Regeneron Pharmaceuticals EBITDA Margin 2021: 60.2%

Regeneron Pharmaceuticals EBITDA margin in 2021 was 60.16%.

See more financial history for Regeneron Pharmaceuticals (REGN).

Sector peers by EBITDA Margin

Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest EBITDA margin

Frequently asked questions

Regeneron Pharmaceuticals (REGN) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation